MARKET

XNCR

XNCR

Xencor
NASDAQ
16.22
+0.09
+0.56%
Pre Market: 16.74 +0.52 +3.21% 08:00 02/13 EST
OPEN
15.82
PREV CLOSE
16.13
HIGH
16.25
LOW
15.73
VOLUME
24
TURNOVER
0
52 WEEK HIGH
27.24
52 WEEK LOW
15.31
MARKET CAP
1.14B
P/E (TTM)
-5.0689
1D
5D
1M
3M
1Y
5Y
1D
XENCOR INC: TO RESTATE AFFECTED FINANCIAL STATEMENTS TO ADDRESS FOREGOING AND WILL PREPARE AMENDMENTS TO EACH OF PRIOR FILINGS
Reuters · 15m ago
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 2d ago
Weekly Report: what happened at XNCR last week (0203-0207)?
Weekly Report · 3d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 02/06 12:05
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 02/05 12:05
Weekly Report: what happened at XNCR last week (0127-0131)?
Weekly Report · 02/03 10:14
Xencor: Substantial Promise, Slow Progress
Seeking Alpha · 01/30 16:57
Weekly Report: what happened at XNCR last week (0120-0124)?
Weekly Report · 01/27 10:15
More
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Webull offers Xencor Inc stock information, including NASDAQ: XNCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XNCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XNCR stock methods without spending real money on the virtual paper trading platform.